Pharmaceuticals policy

Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

Retrieved on: 
Thursday, July 22, 2021

SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, todayannounced it will report its financial results for the second quarter ended June 30, 2021, after the financial markets close onThursday, August 5, 2021.

Key Points: 
  • SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc.(Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, todayannounced it will report its financial results for the second quarter ended June 30, 2021, after the financial markets close onThursday, August 5, 2021.
  • The Companys management team is scheduled to host a conference call and webcast at4:30 p.m. ETonThursday, August 5, 2021.
  • To access the call, please dial 888-394-8218 in theU.S.or 323-794-2588 outside theU.S.and provide the conference ID number: 5960603.
  • Following the live webcast, an archived version of the call will be available on the website.

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

Retrieved on: 
Thursday, July 22, 2021

A replay of the conference call will be available within two hours of the calls completion and will remain accessible for one-week by dialing 800-695-0974 and entering access code 5412658.

Key Points: 
  • A replay of the conference call will be available within two hours of the calls completion and will remain accessible for one-week by dialing 800-695-0974 and entering access code 5412658.
  • ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals.
  • We focus on niche and high barrier to entry opportunities including controlled substances, oncology products (anti-cancers), hormones and steroids, and complex formulations.
  • For more information, please visit our website www.anipharmaceuticals.com .

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Retrieved on: 
Wednesday, July 21, 2021

BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to INZ-701 for the treatment of ABCC6 Deficiency.

Key Points: 
  • BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to INZ-701 for the treatment of ABCC6 Deficiency.
  • INZ-701, an investigational enzyme replacement therapy (ERT), was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the EMA for the treatment of ENPP1 Deficiency.
  • Orphan Drug Designation in theEuropean Union(EU) is granted by theEuropean Commission based on a positive opinion issued by theEMA Committee for Orphan Medicinal Products (COMP).
  • ABCC6 Deficiency is a rare, severe, inherited disorder caused by mutations in the ABCC6 gene, leading to low levels of PPi.

Statement from the Minister of Health on the Antimicrobial Resistance (AMR) Network Report

Retrieved on: 
Tuesday, July 20, 2021

OTTAWA, ON, July 20, 2021 /CNW/ - The Honourable Patty Hajdu, Minister of Health, today issued the following statement.

Key Points: 
  • OTTAWA, ON, July 20, 2021 /CNW/ - The Honourable Patty Hajdu, Minister of Health, today issued the following statement.
  • The antimicrobial (AMR) Network recently released its final report, Strengthening Governance of the Antimicrobial Resistance Response Across One Health in Canada.
  • The AMR Network was funded by the Public Health Agency of Canada (PHAC) to explore governance models that unite diverse stakeholders in this important work.
  • Antimicrobial resistance is a complex global challenge, and this report will help all parties move toward a One Health approach to tackle this universal issue.

Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America

Retrieved on: 
Tuesday, July 20, 2021

MEXICO CITY, July 20, 2021 /PRNewswire/ --m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil.

Key Points: 
  • MEXICO CITY, July 20, 2021 /PRNewswire/ --m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil.
  • This collaboration reinforces m8 Pharmaceuticals' and Pharmanovia's mutual focus to strengthen the presence of their medicines in Latin America, bringing innovative and proven treatments with greater access to patients and caregivers throughout the region.
  • Regarding the collaboration Amit Patel, Pharmanovia's CEO said "Having had the pleasure of working with the M8 team in the past, we are looking forward to this extended collaboration that strengthens our position in Latin America.
  • m8 is a specialty biopharmaceutical company focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico.

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

Retrieved on: 
Tuesday, July 20, 2021

The continuation of pass-through status by the CMS is an important step as we continue to execute on our commercial strategy of expanding the use of DEXYCU by physicians for their patients.

Key Points: 
  • The continuation of pass-through status by the CMS is an important step as we continue to execute on our commercial strategy of expanding the use of DEXYCU by physicians for their patients.
  • Drugs that are administered as part of the cataract surgery procedure can be covered under a CMS administered transitional-pass-through payment.
  • The pass-through payment was established by the U.S. government to help foster innovative drug development.
  • About EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders.

Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China

Retrieved on: 
Tuesday, July 20, 2021

Through this collaboration, Everest will leverage MediTrust's Pharmacy Benefit Management expertise to administer patients' pharmacy plans and help them safely and conveniently get the medications they need.

Key Points: 
  • Through this collaboration, Everest will leverage MediTrust's Pharmacy Benefit Management expertise to administer patients' pharmacy plans and help them safely and conveniently get the medications they need.
  • Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets.
  • It is committed to helping patients solve medical payment problems through innovative payment methods and helping patients manage medical expenditures more efficiently.
  • MediTrust pioneers a business model of "Internet + medical + medicine + insurance" to provide values to patients around innovative payment, commercial insurance PBM, pharmaceutical benefits, and health insurance.

Fixing Potholes Shouldn’t Cost Seniors More at the Pharmacy Counter

Retrieved on: 
Monday, July 19, 2021

Delaying or eliminating Part D rebate reforms aimed at lowering out-of-pocket costs for seniors at the pharmacy counter is not a defendable 'pay for' to fund infrastructure.

Key Points: 
  • Delaying or eliminating Part D rebate reforms aimed at lowering out-of-pocket costs for seniors at the pharmacy counter is not a defendable 'pay for' to fund infrastructure.
  • Rebates lower drug costs for insurers, but patients taking the medicines often do not benefit from rebates or other discounts.
  • With rebate reforms, Medicare beneficiaries would finally see their drug spending go down at the pharmacy counter as savings from rebates and other discounts on medicines have to be shared with beneficiaries.
  • Lowering out-of-pocket costs improves medication adherence, which in turn lowers total healthcare spending and reduces the burden of illness.

Navitus Health Solutions Continues Growth with Acquisitions of EpiphanyRx and Quality Drug Clinical Care

Retrieved on: 
Monday, July 19, 2021

Lumicera Health Services, Navitus wholly-owned specialty pharmacy, has also purchased Quality Drug Clinical Care, a specialty pharmacy serving patients with HIV in Irvine, CA, to better serve patients located in the western United States.

Key Points: 
  • Lumicera Health Services, Navitus wholly-owned specialty pharmacy, has also purchased Quality Drug Clinical Care, a specialty pharmacy serving patients with HIV in Irvine, CA, to better serve patients located in the western United States.
  • Navitus continues to evolve and grow to deliver the highest quality clinical value and lowest net costs to our customers through our full pass-through, transparent business model, said David Fields, President & CEO, Navitus.
  • We are thrilled that Quality Drug Clinical Care has joined our growing network of Lumicera specialty pharmacies, said Sharon Faust, Vice President, Specialty Pharmacy, Lumicera Health Services.
  • Quality Drug Clinical Care helps its customer with their specialty medication and provide ongoing, personalized support.

CHOP Researchers Establish Novel Approach for Developing New Antibiotics

Retrieved on: 
Monday, July 19, 2021

PHILADELPHIA, July 19, 2021 /PRNewswire/ --Researchers at Children's Hospital of Philadelphia (CHOP) have developed a novel method for producing new antibiotics to combat resistant bacteria.

Key Points: 
  • PHILADELPHIA, July 19, 2021 /PRNewswire/ --Researchers at Children's Hospital of Philadelphia (CHOP) have developed a novel method for producing new antibiotics to combat resistant bacteria.
  • Through an approach that would target bacteria with an antibiotic that is masked by a prodrug, which the bacteria would themselves remove, the researchers identified a method that would allow for development of new, effective antibiotics that could overcome issues of resistance.
  • "Using structure-guided design, we have developed a new way to design better antibiotics.
  • To tackle this problem, the researchers took a new approach that relied on exploiting bacterial metabolism, processes that are essential for bacteria to thrive.